Novartis’ Glivec case in India delayed after judge disqualifies himself
This article was originally published in Scrip
A Supreme Court judge set to hear a case involving Novartis' challenge against Section 3d, a controversial provision in India's patent law, has recused himself – a move that is now expected to require a new judge to hear the case at a later date.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.